1 / 10

Immunotherapy

Immunotherapy. Personal statistics (updated, 2013) John Weisnagel, M.D. Database . Sept 1992-Dec 2012: 31,150 patients Undergoing immunotherapy: 2,533 pts (8%) Perennial Rx (all-year long): 1,490 (58.8%)

hope
Télécharger la présentation

Immunotherapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Immunotherapy Personal statistics (updated, 2013) John Weisnagel, M.D.

  2. Database • Sept 1992-Dec 2012: 31,150 patients • Undergoing immunotherapy: 2,533 pts (8%) • Perennial Rx (all-year long): 1,490 (58.8%) • Pre-seasonal Rx (one injection per week (for 4 or 9 weeks depending on type of Rx, 1-2 months preceding the specific pollen season): 1020 (40.2%) • 23 pts having rec’d both types of treatment.

  3. Efficacy of immunotherapy • Of the 2,533 treated since 1992, • 1046 replied to the question of the effect of their treatment (excellent, very good, good, slight or no change) when reminders were sent them about renewals • Treatment was: • Perennial in 596 • Pre-seasonal in 450

  4. Perennial Treatment • 596 patients: • Asthma: 53 (8.8%) • Asthma + pollinosis: 74 (12.4%) • Asthma + rhinitis: 86 (14.4%) • Pollinosis: 155 (26%) • Rhinitis: 225 (37.7%)

  5. Efficacy of Perennial treatment in 596 patients

  6. Pre-seasonal Treatment • 450 patients with pollen allergy, some with associated asthma: Reported effect: Excellent in 82 (18.2%) Very good in 135 (30%) Good in 111 (24.6%) Slight in 48 (10.6%) Ineffective in 24 (5.3%)

  7. Efficacy summary • Perennial treatment averaged : • 18.5% for slight improvement • 28.9% for good “ • 30.3% for very good “ • 10.1% for excellent “ • while ineffective in only 11.8% • Pre-seasonal treatment averaged: • 10.6% for slight improvement • 24.6% for good “ • 30% for very good “ • 18.2% for excellent “ • while ineffective in only 5.3%

  8. Pre-seasonals • Center-Al™ • Suspal™ • Pollinex R™ • Other tyrosine preps.

  9. Perennials • Mixtures: • House dust mite + pollens • House dust mite + molds • House dust mite + pollens + molds

  10. Bottom line • These personal statistics, though anecdotal, reflect the conclusion of the many studies published on the benefit of immunotherapy. • Both forms of therapy, perennial and pre-seasonal have similar benefits. • Immunotherapy is still an effective treatment in respiratory allergy, and should be considered when pharmaceutical therapy is inadequate.

More Related